Ethical challenges in the therapeutic application of classical psychedelics for pediatric health conditions: A comprehensive review
DOI:
https://doi.org/10.14295/bjs.v4i10.785Keywords:
classical psychedelics, psychedelic therapy, clinical research, adolescents, bioethicsAbstract
Classical psychedelics encompass psilocybin, lysergic acid diethylamide (LSD), N, N-dimethyltryptamine (DMT), and mescaline and are psychoactive substances that primarily function as agonists at the serotonin 5-hydroxytryptamine receptors (5-HT). In the immediate term, they modify perception, cognition, emotional state, social processing, and introspection, leading to a subjective mystical encounter. They also yield enduring effects by mediating neural plasticity. A renaissance in the potential benefits of using psychedelics, especially for psychiatric disorders, has led to clinical trials with adults. When considering a possible equivalent application of classical psychedelics for pediatric conditions, autonomy, beneficence, non-maleficence, and justice have to be contemplated, following the framework of Beauchamp and Childress. The purpose of this study was to provide a comprehensive review of the use of classical psychedelics, hence providing a balanced evaluation of the ethical considerations surrounding the administration of psychedelic compounds to pediatric populations. We summarized evidence indicating that classical psychedelics have shown efficacy in treating various disorders in adults, with ongoing research exploring their potential for additional conditions. While this suggests they could offer benefits for children, the current research remains preliminary, with uncertain outcomes and significant limitations. These factors highlight the ethical and practical challenges of applying such treatments to children, a particularly vulnerable population.
References
Aday, J. S., Davis, A. K., Mitzkovitz, C. M., Bloesch, E. K., & Davoli, C. C. (2021). Predicting reactions to psychedelic drugs: A systematic review of states and traits related to acute drug effects. ACS Pharmacology & Translational Science, 4(2), 424-435. https://doi.org/10.1021/acsptsci.1c00014 DOI: https://doi.org/10.1021/acsptsci.1c00014
Administration (TGA), T. G. (2023, February 3). Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists | Therapeutic Goods Administration (TGA) [Text]. Therapeutic Goods Administration (TGA). https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists
Akabayashi, A., & Nakazawa, E. (2022). Autonomy in Japan: What does it look like? Asian Bioethics Review, 14(4), 317-336. https://doi.org/10.1007/s41649-022-00213-6 DOI: https://doi.org/10.1007/s41649-022-00213-6
Allen, J., Balfour, R., Bell, R., & Marmot, M. (2014). Social determinants of mental health. International Review of Psychiatry (Abingdon, England), 26(4), 392–407. https://doi.org/10.3109/09540261.2014.928270 DOI: https://doi.org/10.3109/09540261.2014.928270
Amann, J., Blasimme, A., Vayena, E., Frey, D., Madai, V. I., & the Precise4Q consortium. (2020). Explainability for artificial intelligence in healthcare: A multidisciplinary perspective. BMC Medical Informatics and Decision Making, 20(1), 310. https://doi.org/10.1186/s12911-020-01332-6 DOI: https://doi.org/10.1186/s12911-020-01332-6
Andrade, R., & Weber, E. T. (2010). Htr2a Gene and 5-HT2A Receptor Expression in the Cerebral Cortex Studied Using Genetically Modified Mice. Frontiers in Neuroscience, 4. https://doi.org/10.3389/fnins.2010.00036 DOI: https://doi.org/10.3389/fnins.2010.00036
Bates, M. L. S., & Trujillo, K. A. (2021). Use and abuse of dissociative and psychedelic drugs in adolescence. Pharmacology, Biochemistry, and Behavior, 203, 173129. https://doi.org/10.1016/j.pbb.2021.173129 DOI: https://doi.org/10.1016/j.pbb.2021.173129
Beauchamp, T., & and Childress, J. (2019). Principles of Biomedical Ethics: Marking Its Fortieth Anniversary. The American Journal of Bioethics, 19(11), 9–12. https://doi.org/10.1080/15265161.2019.1665402 DOI: https://doi.org/10.1080/15265161.2019.1665402
Bitsko, R. H. (2022). Mental Health Surveillance Among Children—United States, 2013–2019. MMWR Supplements, 71. https://doi.org/10.15585/mmwr.su7102a1 DOI: https://doi.org/10.15585/mmwr.su7102a1
Bosch, O. G., Halm, S., & Seifritz, E. (2022). Psychedelics in the treatment of unipolar and bipolar depression. International Journal of Bipolar Disorders, 10(1), 18. https://doi.org/10.1186/s40345-022-00265-5 DOI: https://doi.org/10.1186/s40345-022-00265-5
Brito-da-Costa, A. M., Dias-da-Silva, D., Gomes, N. G. M., Dinis-Oliveira, R. J., & Madureira-Carvalho, Á. (2020). Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact. Pharmaceuticals (Basel, Switzerland), 13(11), 334. https://doi.org/10.3390/ph13110334 DOI: https://doi.org/10.3390/ph13110334
Byock, I. (2018). Taking Psychedelics Seriously. Journal of Palliative Medicine, 21(4), 417–421. https://doi.org/10.1089/jpm.2017.0684 DOI: https://doi.org/10.1089/jpm.2017.0684
Calvey, T., & Howells, F. M. (2018). An introduction to psychedelic neuroscience. Progress in Brain Research, 242, 1–23. https://doi.org/10.1016/bs.pbr.2018.09.013 DOI: https://doi.org/10.1016/bs.pbr.2018.09.013
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., & Drevets, W. C. (2018). Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. The American Journal of Psychiatry, 175(7), 620–630. https://doi.org/10.1176/appi.ajp.2018.17060720 DOI: https://doi.org/10.1176/appi.ajp.2018.17060720
Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelicss. Pharmacological Reviews, 71(3), 316–344. https://doi.org/10.1124/pr.118.017160 DOI: https://doi.org/10.1124/pr.118.017160
Carhart-Harris, R. L., & Goodwin, G. M. (2017). The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology, 42(11), 2105–2113. https://doi.org/10.1038/npp.2017.84 DOI: https://doi.org/10.1038/npp.2017.84
Carter, S., Packard, G., Coghlan, C., George, J. R., Brown, A. J., Ching, T. H. W., Julian, J., & Maples-Keller, J. L. (2023). Perceptions of psychedelic-assisted therapy among Black Americans. Journal of Mood & Anxiety Disorders, 4, 100023. https://doi.org/10.1016/j.xjmad.2023.100023 DOI: https://doi.org/10.1016/j.xjmad.2023.100023
Cassels, B. K., & Sáez-Briones, P. (2018). Dark Classics in Chemical Neuroscience: Mescaline. ACS Chemical Neuroscience, 9(10), 2448–2458. https://doi.org/10.1021/acschemneuro.8b00215 DOI: https://doi.org/10.1021/acschemneuro.8b00215
Chattopadhyaya, B., & Cristo, G. D. (2012). GABAergic Circuit Dysfunctions in Neurodevelopmental Disorders. Frontiers in Psychiatry, 3, 51. https://doi.org/10.3389/fpsyt.2012.00051 DOI: https://doi.org/10.3389/fpsyt.2012.00051
Cheung, C.-K., & Tsang, E. Y.-H. (2023). Conditions for Social Exclusion Leading to Distress Change in Chinese Lesbian, Gay, and Bisexual (LGB) People. International Journal of Environmental Research and Public Health, 20(10). Scopus. https://doi.org/10.3390/ijerph20105911 DOI: https://doi.org/10.3390/ijerph20105911
Cortese, S., Adamo, N., Giovane, C. D., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., Hollis, C., Simonoff, E., Zuddas, A., Barbui, C., Purgato, M., Steinhausen, H.-C.,
Shokraneh, F., Xia, J., & Cipriani, A. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738. https://doi.org/10.1016/S2215-0366(18)30269-4 DOI: https://doi.org/10.1016/S2215-0366(18)30269-4
Council for International Organizations of Medical Sciences (CIOMS). (2016). International Ethical Guidelines for Health-related Research involving Humans. Council for International Organizations of Medical Sciences (CIOMS). https://doi.org/10.56759/rgxl7405 DOI: https://doi.org/10.56759/rgxl7405
Davis, J. M., Giakas, W. J., Qu, J., Prasad, P., & Leucht, S. (2011). Should We Treat Depression with drugs or psychological interventions? A Reply to Ioannidis. Philosophy, Ethics, and Humanities in Medicine : PEHM, 6, 8. https://doi.org/10.1186/1747-5341-6-8 DOI: https://doi.org/10.1186/1747-5341-6-8
De Gregorio, D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2021). Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine. The Journal of Neuroscience, 41(5), 891–900. https://doi.org/10.1523/JNEUROSCI.1659-20.2020 DOI: https://doi.org/10.1523/JNEUROSCI.1659-20.2020
De Gregorio, D., Enns, J. P., Nuñez, N. A., Posa, L., & Gobbi, G. (2018). d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders. Progress in Brain Research, 242, 69–96. https://doi.org/10.1016/bs.pbr.2018.07.008 DOI: https://doi.org/10.1016/bs.pbr.2018.07.008
de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021). Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. Frontiers in Psychiatry, 12, 724606. https://doi.org/10.3389/fpsyt.2021.724606 DOI: https://doi.org/10.3389/fpsyt.2021.724606
Dell, M. L. (2012). Child and adolescent depression: Psychotherapeutic, ethical, and related nonpharmacologic considerations for general psychiatrists and others who prescribe. The Psychiatric Clinics of North America, 35(1), 181–201. https://doi.org/10.1016/j.psc.2011.12.002 DOI: https://doi.org/10.1016/j.psc.2011.12.002
Dos Santos, R. G., Bouso, J. C., Alcázar-Córcoles, M. Á., & Hallak, J. E. C. (2018). Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews. Expert Review of Clinical Pharmacology, 11(9), 889–902. https://doi.org/10.1080/17512433.2018.1511424 DOI: https://doi.org/10.1080/17512433.2018.1511424
dos Santos, R. G., Bouso, J. C., Rocha, J. M., Rossi, G. N., & Hallak, J. E. (2021). The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges. Risk Management and Healthcare Policy, 14, 901–910. https://doi.org/10.2147/RMHP.S300656 DOI: https://doi.org/10.2147/RMHP.S300656
Edelsohn, G. A., & Sisti, D. (2023). Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment. Perspectives in Biology and Medicine, 66(1), 129–144. https://doi.org/10.1353/pbm.2023.0007 DOI: https://doi.org/10.1353/pbm.2023.0007
ClinicalTrials.gov. (n.d.). Retrieved June 6, 2025, from https://www.clinicaltrials.gov/search?intr=psilocybin)
Family, N., Maillet, E. L., Williams, L. T. J., Krediet, E., Carhart-Harris, R. L., Williams, T. M., Nichols, C. D., Goble, D. J., & Raz, S. (2020). Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology, 237(3), 841–853. https://doi.org/10.1007/s00213-019-05417-7 DOI: https://doi.org/10.1007/s00213-019-05417-7
Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., Newcorn, J. H., Gignac, M., Al Saud, N. M., Manor, I., Rohde, L. A., Yang, L., Cortese, S., Almagor, D., Stein, M. A., Albatti, T. H., Aljoudi, H. F., Alqahtani, M. M. J., Asherson, P., … Wang, Y. (2021). The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews, 128, 789–818. https://doi.org/10.1016/j.neubiorev.2021.01.022 DOI: https://doi.org/10.1016/j.neubiorev.2021.01.022
Freedman, A. M., Ebin, E. V., & Wilson, E. A. (1962). Autistic schizophrenic children. An experiment in the use of d-lysergic acid diethylamide (LSD-25). Archives of General Psychiatry, 6, 203–213. https://doi.org/10.1001/archpsyc.1962.01710210019003 DOI: https://doi.org/10.1001/archpsyc.1962.01710210019003
Garel, N., Thibault Lévesque, J., Sandra, D. A., Lessard-Wajcer, J., Solomonova, E., Lifshitz, M., Richard-Devantoy, S., & Greenway, K. T. (2023). Imprinting: Expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings. Frontiers in Human Neuroscience, 17. https://doi.org/10.3389/fnhum.2023.1200393 DOI: https://doi.org/10.3389/fnhum.2023.1200393
Gattuso, J. J., Perkins, D., Ruffell, S., Lawrence, A. J., Hoyer, D., Jacobson, L. H., Timmermann, C., Castle, D., Rossell, S. L., Downey, L. A., Pagni, B. A., Galvão-Coelho, N. L., Nutt, D., & Sarris, J. (2023). Default Mode Network Modulation by Psychedelics: A Systematic Review. The International Journal of Neuropsychopharmacology, 26(3), 155–188. https://doi.org/10.1093/ijnp/pyac074 DOI: https://doi.org/10.1093/ijnp/pyac074
Geiger, H. A., Wurst, M. G., & Daniels, R. N. (2018). DARK Classics in Chemical Neuroscience: Psilocybin. ACS Chemical Neuroscience, 9(10), 2438–2447. https://doi.org/10.1021/acschemneuro.8b00186 DOI: https://doi.org/10.1021/acschemneuro.8b00186
Genuis, Q. I. T. (2021). A Genealogy of Autonomy: Freedom, Paternalism, and the Future of the Doctor-Patient Relationship. The Journal of Medicine and Philosophy, 46(3), 330–349. https://doi.org/10.1093/jmp/jhab004 DOI: https://doi.org/10.1093/jmp/jhab004
Golub, A., Bennett, A. S., & Elliott, L. (2015). Beyond America’s War on Drugs: Developing Public Policy to Navigate the Prevailing Pharmacological Revolution. AIMS Public Health, 2(1), 142–160. https://doi.org/10.3934/publichealth.2015.1.142 DOI: https://doi.org/10.3934/publichealth.2015.1.142
Greif, A., & Šurkala, M. (2020). Compassionate use of psychedelics. Medicine, Health Care, and Philosophy, 23(3), 485–496. https://doi.org/10.1007/s11019-020-09958-z DOI: https://doi.org/10.1007/s11019-020-09958-z
Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022). Psychedelics and Neural Plasticity: Therapeutic Implications. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 42(45), 8439–8449. https://doi.org/10.1523/JNEUROSCI.1121-22.2022 DOI: https://doi.org/10.1523/JNEUROSCI.1121-22.2022
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology (Oxford, England), 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513 DOI: https://doi.org/10.1177/0269881116675513
Halberstadt, A. L. (2015). Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural Brain Research, 277, 99–120. https://doi.org/10.1016/j.bbr.2014.07.016 DOI: https://doi.org/10.1016/j.bbr.2014.07.016
Halpern, J. H., & Pope, H. G. (2003). Hallucinogen persisting perception disorder: What do we know after 50 years? Drug and Alcohol Dependence, 69(2), 109–119. https://doi.org/10.1016/s0376-8716(02)00306-x DOI: https://doi.org/10.1016/S0376-8716(02)00306-X
Hamill, J., Hallak, J., Dursun, S. M., & Baker, G. (2019). Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness. Current Neuropharmacology, 17(2), 108–128. https://doi.org/10.2174/1570159X16666180125095902 DOI: https://doi.org/10.2174/1570159X16666180125095902
Johnson, A. M., Jones, S. B., Duncan, P. W., Bushnell, C. D., Coleman, S. W., Mettam, L. H., Kucharska-Newton, A. M., Sissine, M. E., & Rosamond, W. D. (2018). Hospital recruitment for a pragmatic cluster-randomized clinical trial: Lessons learned from the COMPASS study. Trials, 19(1). https://doi.org/10.1186/s13063-017-2434-1 DOI: https://doi.org/10.1186/s13063-017-2434-1
Johnson, M. W., & Griffiths, R. R. (2017). Potential Therapeutic Effects of Psilocybin. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 14(3), 734–740. https://doi.org/10.1007/s13311-017-0542-y DOI: https://doi.org/10.1007/s13311-017-0542-y
Kelmendi, B., Kaye, A. P., Pittenger, C., & Kwan, A. C. (2022). Psychedelics. Current Biology: CB, 32(2), R63–R67. https://doi.org/10.1016/j.cub.2021.12.009 DOI: https://doi.org/10.1016/j.cub.2021.12.009
Kenny, B. J., Preuss, C. V., & Zito, P. M. (2025). Controlled Substance Schedules. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK538457/
Ko, K., Kopra, E. I., Cleare, A. J., & Rucker, J. J. (2023). Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. Journal of Affective Disorders, 322, 194–204. https://doi.org/10.1016/j.jad.2022.09.168 DOI: https://doi.org/10.1016/j.jad.2022.09.168
Koelch, M., Schnoor, K., & Fegert, J. M. (2008). Ethical issues in psychopharmacology of children and adolescents. Current Opinion in Psychiatry, 21(6), 598–605. https://doi.org/10.1097/YCO.0b013e328314b776 DOI: https://doi.org/10.1097/YCO.0b013e328314b776
Kraus, L. J., & Mehlinger, R. (2005). Black box blues: Kids and antidepressants. The Virtual Mentor: VM, 7(3), virtualmentor.2005.7.3.jdsc1-0503. https://doi.org/10.1001/virtualmentor.2005.7.3.jdsc1-0503 DOI: https://doi.org/10.1001/virtualmentor.2005.7.3.jdsc1-0503
Kuypers, K. P. C. (2020). The therapeutic potential of microdosing psychedelics in depression. Therapeutic Advances in Psychopharmacology, 10, 2045125320950567. https://doi.org/10.1177/2045125320950567 DOI: https://doi.org/10.1177/2045125320950567
Kwan, A. C., Olson, D. E., Preller, K. H., & Roth, B. L. (2022). The neural basis of psychedelic action. Nature Neuroscience, 25(11), 1407–1419. https://doi.org/10.1038/s41593-022-01177-4 DOI: https://doi.org/10.1038/s41593-022-01177-4
Libânio Osório Marta, R. F. (2019). Metabolism of lysergic acid diethylamide (LSD): An update. Drug Metabolism Reviews, 51(3), 378–387. https://doi.org/10.1080/03602532.2019.1638931 DOI: https://doi.org/10.1080/03602532.2019.1638931
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., Lin, K., Ho, R., Rosenblat, J. D., Castle, D., & McIntyre, R. S. (2022). Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS Drugs, 36(1), 17–30. https://doi.org/10.1007/s40263-021-00877-y DOI: https://doi.org/10.1007/s40263-021-00877-y
Lowe, H., Toyang, N., Steele, B., Grant, J., Ali, A., Gordon, L., & Ngwa, W. (2022). Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders. Molecules (Basel, Switzerland), 27(8), 2520. https://doi.org/10.3390/molecules27082520 DOI: https://doi.org/10.3390/molecules27082520
Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., & Gordon, L. (2021). The Therapeutic Potential of Psilocybin. Molecules (Basel, Switzerland), 26(10), 2948. https://doi.org/10.3390/molecules26102948 DOI: https://doi.org/10.3390/molecules26102948
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., Duim, W. C., Dennis, M. Y., McAllister, A. K., Ori-McKenney, K. M., Gray, J. A., & Olson, D. E. (2018). Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports, 23(11), 3170–3182. https://doi.org/10.1016/j.celrep.2018.05.022 DOI: https://doi.org/10.1016/j.celrep.2018.05.022
Mackey, K. M., Anderson, J. K., Williams, B. E., Ward, R. M., & Parr, N. J. (2022). Evidence Brief: Psychedelic Medications for Mental Health and Substance Use Disorders. Department of Veterans Affairs (US). http://www.ncbi.nlm.nih.gov/books/NBK586533/
McCullough, L. B. (2020). Beneficence and Wellbeing: A Critical Appraisal. The American Journal of Bioethics: AJOB, 20(3), 65–68. https://doi.org/10.1080/15265161.2020.1714817 DOI: https://doi.org/10.1080/15265161.2020.1714817
McGovern, H. T., Leptourgos, P., Hutchinson, B. T., & Corlett, P. R. (2022). Do psychedelics change beliefs? Psychopharmacology, 239(6), 1809–1821. https://doi.org/10.1007/s00213-022-06153-1 DOI: https://doi.org/10.1007/s00213-022-06153-1
Meghani, S. H., Byun, E., & Chittams, J. (2014). Conducting Research with Vulnerable Populations: Cautions and Considerations in Interpreting Outliers in Disparities Research. AIMS Public Health, 1(1), 25–32. https://doi.org/10.3934/publichealth.2014.1.25 DOI: https://doi.org/10.3934/publichealth.2014.1.25
Meier, L. J., Hein, A., Diepold, K., & Buyx, A. (2022). Algorithms for Ethical Decision-Making in the Clinic: A Proof of Concept. The American Journal of Bioethics: AJOB, 22(7), 4–20. https://doi.org/10.1080/15265161.2022.2040647 DOI: https://doi.org/10.1080/15265161.2022.2040647
Mental health of adolescents. (n.d.). Retrieved June 6, 2025, from https://www.who.int/news-room/fact-sheets/detail/adolescent-mental-health
Michaels, T. I., Purdon, J., Collins, A., & Williams, M. T. (2018). Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature. BMC Psychiatry, 18(1), 245. https://doi.org/10.1186/s12888-018-1824-6 DOI: https://doi.org/10.1186/s12888-018-1824-6
Mofatteh, M. (2020). Risk factors associated with stress, anxiety, and depression among university undergraduate students. AIMS Public Health, 8(1), 36–65. https://doi.org/10.3934/publichealth.2021004 DOI: https://doi.org/10.3934/publichealth.2021004
Muttoni, S., Ardissino, M., & John, C. (2019). Classical psychedelics for the treatment of depression and anxiety: A systematic review. Journal of Affective Disorders, 258, 11–24. https://doi.org/10.1016/j.jad.2019.07.076 DOI: https://doi.org/10.1016/j.jad.2019.07.076
Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478 DOI: https://doi.org/10.1124/pr.115.011478
Nichols, D. E. (2018). Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD). ACS Chemical Neuroscience, 9(10), 2331–2343. https://doi.org/10.1021/acschemneuro.8b00043 DOI: https://doi.org/10.1021/acschemneuro.8b00043
Nichols, D. E., & Walter, H. (2021). The History of Psychedelics in Psychiatry. Pharmacopsychiatry, 54(4), 151–166. https://doi.org/10.1055/a-1310-3990 DOI: https://doi.org/10.1055/a-1310-3990
Oregon Health Authority: Oregon Psilocybin Services—2023 Rulemaking: Prevention and Wellness: State of Oregon. (n.d.). Retrieved May 25, 2025, from https://www.oregon.gov/oha/ph/preventionwellness/pages/psilocybin-2023-rulemaking.aspx
Pilecki, B., Luoma, J. B., Bathje, G. J., Rhea, J., & Narloch, V. F. (2021). Ethical and legal issues in psychedelic harm reduction and integration therapy. Harm Reduction Journal, 18(1), 40. https://doi.org/10.1186/s12954-021-00489-1 DOI: https://doi.org/10.1186/s12954-021-00489-1
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research. (2020). Psychedelics and Psychedelic-Assisted Psychotherapy. The American Journal of Psychiatry, 177(5), 391–410. https://doi.org/10.1176/appi.ajp.2019.19010035 DOI: https://doi.org/10.1176/appi.ajp.2019.19010035
Remien, K., & Kanchan, T. (2025). Parental Consent. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK555889/
Rhead, Jo. C. (1977). The Use of Psychedelic Drugs in the Treatment of Severely Disturbed Children: A Review. Journal of Psychedelic Drugs, 9(2), 93–101. https://doi.org/10.1080/02791072.1977.10472034 DOI: https://doi.org/10.1080/02791072.1977.10472034
Richard, J., Garcia-Romeu, A., & Henningfield, J. E. (2025). Expanded access to psychedelic treatments: Comparing American and Canadian policies. General Psychiatry, 38(1). https://doi.org/10.1136/gpsych-2024-101894 DOI: https://doi.org/10.1136/gpsych-2024-101894
Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018). Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology, 142, 200–218. https://doi.org/10.1016/j.neuropharm.2017.12.040 DOI: https://doi.org/10.1016/j.neuropharm.2017.12.040
Saad, T. C. (2018). The history of autonomy in medicine from antiquity to principlism. Medicine, Health Care, and Philosophy, 21(1), 125–137. https://doi.org/10.1007/s11019-017-9781-2 DOI: https://doi.org/10.1007/s11019-017-9781-2
Sarparast, A., Thomas, K., Malcolm, B., & Stauffer, C. S. (2022). Drug-drug interactions between psychiatric medications and MDMA or psilocybin: A systematic review. Psychopharmacology, 239(6), 1945–1976. https://doi.org/10.1007/s00213-022-06083-y DOI: https://doi.org/10.1007/s00213-022-06083-y
Schindler, E. A. D. (2022). Psychedelics in the Treatment of Headache and Chronic Pain Disorders. Current Topics in Behavioral Neurosciences, 56, 261–285. https://doi.org/10.1007/7854_2022_365 DOI: https://doi.org/10.1007/7854_2022_365
Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022). Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology (Oxford, England), 36(3), 258–272. https://doi.org/10.1177/02698811211069100 DOI: https://doi.org/10.1177/02698811211069100
Selemon, L. D. (2013). A role for synaptic plasticity in the adolescent development of executive function. Translational Psychiatry, 3(3), e238. https://doi.org/10.1038/tp.2013.7 DOI: https://doi.org/10.1038/tp.2013.7
Shea, M. (2020). Principlism’s Balancing Act: Why the Principles of Biomedical Ethics Need a Theory of the Good. The Journal of Medicine and Philosophy, 45(4–5), 441–470. https://doi.org/10.1093/jmp/jhaa014 DOI: https://doi.org/10.1093/jmp/jhaa014
Shearer, M. C., & Bermingham, S. L. (2008). The ethics of paediatric anti-depressant use: Erring on the side of caution. Journal of Medical Ethics, 34(10), 710–714. https://doi.org/10.1136/jme.2007.023119 DOI: https://doi.org/10.1136/jme.2007.023119
Siegel, J. S., Subramanian, S., Perry, D., Kay, B. P., Gordon, E. M., Laumann, T. O., Reneau, T. R., Metcalf, N. V., Chacko, R. V., Gratton, C., Horan, C., Krimmel, S. R., Shimony, J. S., Schweiger, J. A., Wong, D. F., Bender, D. A., Scheidter, K. M., Whiting, F. I., Padawer-Curry, J. A., … Dosenbach, N. U. F. (2024). Psilocybin desynchronizes the human brain. Nature, 632(8023), 131–138. https://doi.org/10.1038/s41586-024-07624-5 DOI: https://doi.org/10.1038/s41586-024-07624-5
Sigafoos, J., Green, V. A., Edrisinha, C., & Lancioni, G. E. (2007). Flashback to the 1960s: LSD in the treatment of autism. Developmental Neurorehabilitation, 10(1), 75–81. https://doi.org/10.1080/13638490601106277 DOI: https://doi.org/10.1080/13638490601106277
Simmons, J. Q., Benor, D., & Daniel, D. (1972). The variable effects of LSD-25 on the behavior of a heterogeneous group of childhood schizophrenics. Behavioral Neuropsychiatry, 4(1–2), 10-16 passim.
Simmons, J. Q., Leiken, S. J., Lovaas, O. I., Schaeffer, B., & Perloff, B. (1966). Modification of autistic behavior with LSD-25. The American Journal of Psychiatry, 122(11), 1201–1211. https://doi.org/10.1176/ajp.122.11.1201 DOI: https://doi.org/10.1176/ajp.122.11.1201
Spetie, L., & Arnold, L. E. (2007). Ethical issues in child psychopharmacology research and practice: Emphasis on preschoolers. Psychopharmacology, 191(1), 15–26. https://doi.org/10.1007/s00213-006-0685-8 DOI: https://doi.org/10.1007/s00213-006-0685-8
Storebø, O. J., Ramstad, E., Krogh, H. B., Nilausen, T. D., Skoog, M., Holmskov, M., Rosendal, S., Groth, C., Magnusson, F. L., Moreira-Maia, C. R., Gillies, D., Buch Rasmussen, K., Gauci, D., Zwi, M., Kirubakaran, R., Forsbøl, B., Simonsen, E., & Gluud, C. (2015). Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). The Cochrane Database of Systematic Reviews, 2015(11), CD009885. https://doi.org/10.1002/14651858.CD009885.pub2 DOI: https://doi.org/10.1002/14651858.CD009885.pub2
Strauss, P., Cook, A., Watson, V., Winter, S., Whitehouse, A., Albrecht, N., Wright Toussaint, D., & Lin, A. (2021). Mental health difficulties among trans and gender diverse young people with an autism spectrum disorder (ASD): Findings from Trans Pathways. Journal of Psychiatric Research, 137, 360–367. Scopus. https://doi.org/10.1016/j.jpsychires.2021.03.005 DOI: https://doi.org/10.1016/j.jpsychires.2021.03.005
Swanson, L. R. (2018). Unifying Theories of Psychedelic Drug Effects. Frontiers in Pharmacology, 9, 172. https://doi.org/10.3389/fphar.2018.00172 DOI: https://doi.org/10.3389/fphar.2018.00172
Takala, T., & Häyry, M. (2019). Research Ethics and Justice: The Case of Finland. Cambridge Quarterly of Healthcare Ethics: CQ: The International Journal of Healthcare Ethics Committees, 28(3), 551–576. https://doi.org/10.1017/S0963180119000471 DOI: https://doi.org/10.1017/S0963180119000471
Taplin, S., Chalmers, J., Brown, J., Moore, T., Graham, A., & McArthur, M. (2022). Human Research Ethics Committee Experiences and Views About Children’s Participation in Research: Results From the MESSI Study. Journal of Empirical Research on Human Research Ethics: JERHRE, 17(1–2), 70–83. https://doi.org/10.1177/15562646211048294 DOI: https://doi.org/10.1177/15562646211048294
Trust in Healthcare, Medical Mistrust, and Health Outcomes in Times of Health Crisis: A Narrative Review. (n.d.). Retrieved June 6, 2025, from https://www.mdpi.com/2075-4698/14/12/269 DOI: https://doi.org/10.3390/soc14120269
Turner, M. A., Catapano, M., Hirschfeld, S., Giaquinto, C., & Global Research in Paediatrics. (2014). Paediatric drug development: The impact of evolving regulations. Advanced Drug Delivery Reviews, 73, 2–13. https://doi.org/10.1016/j.addr.2014.02.003 DOI: https://doi.org/10.1016/j.addr.2014.02.003
Vamvakopoulou, I. A., Narine, K. A. D., Campbell, I., Dyck, J. R. B., & Nutt, D. J. (2023). Mescaline: The forgotten psychedelic. Neuropharmacology, 222, 109294. https://doi.org/10.1016/j.neuropharm.2022.109294 DOI: https://doi.org/10.1016/j.neuropharm.2022.109294
Vargas, T., Rakhshan Rouhakhtar, P. J., Schiffman, J., Zou, D. S., Rydland, K. J., & Mittal, V. A. (2020). Neighborhood crime, socioeconomic status, and suspiciousness in adolescents and young adults at Clinical High Risk (CHR) for psychosis. Schizophrenia Research, 215, 74–80. Scopus. https://doi.org/10.1016/j.schres.2019.11.024 DOI: https://doi.org/10.1016/j.schres.2019.11.024
Vargas-Perez, H., Grieder, T. E., & van der Kooy, D. (2023). Neural Plasticity in the Ventral Tegmental Area, Aversive Motivation during Drug Withdrawal and Hallucinogenic Therapy. Journal of Psychoactive Drugs, 55(1), 62–72. https://doi.org/10.1080/02791072.2022.2033889 DOI: https://doi.org/10.1080/02791072.2022.2033889
Vollenweider, F. X., & Preller, K. H. (2020). Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nature Reviews. Neuroscience, 21(11), 611–624. https://doi.org/10.1038/s41583-020-0367-2 DOI: https://doi.org/10.1038/s41583-020-0367-2
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Pinelopi Vlotinou, Konstantinos Christodoulou , Anna Tsiakiri, Foteini Christidi, Aspasia Serdari
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
